Skip to main content

Advertisement

Table 4 Comparison of the backgrounds of dapagliflozin group with or without amelioration of MAGE

From: A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Variables Dapagliflozin (n = 14) p value
Amelioration (Δ MAGE < 0) (n = 6) Deterioration (Δ MAGE ≥ 0) (n = 8)
Baseline MAGE (mg dL−1) 100.2 ± 25.3 75.3 ± 29.2 0.11
Age (years) 62.7 ± 8.9 63.3 ± 7.3 0.90
BMI (kg m−2) 25.9 ± 4.7 26.9 ± 4.9 0.71
Duration of disease (years) 16.7 ± 4.5 17.5 ± 10.0 0.84
HbA1c (%) 7.0 ± 0.5 7.2 ± 1.0 0.65
1,5-Anhydro-d-glucitol (μg mL−1) 8.3 ± 4.5 8.8 ± 5.1 0.85
ALT (IU L−1) 42.2 ± 39.7 35.8 ± 22.6 0.73
Estimated GFR [mL min−1 (1.73 m2)−1] 79.7 ± 12.5 62.2 ± 11.7 0.02
The total insulin dose (U) 21.7 ± 21.3 13.1 ± 7.8 0.38
  1. Values are mean ± SD. p value of amelioration vs deterioration groups
  2. BMI body mass index, ALT alanine-aminotransferase, GFR glomerular filtration rate